Supporting Treatment Outcomes Among PWID

Inclusion Criteria: * Registered for care at an Integrated Care Center (ICC) in one of the 7 field sites. * Active HCV infection confirmed by a detectable HCV RNA by polymerase chain reaction (PCR) (HCV RNA ≥ 30 copies/ml) within 90 days prior to study entry. * Liver disease stage defined as non-cirrhotic or compensated cirrhotic (metric/diagnostic criteria used for fibrosis staging) within 90 days prior to study entry. i. Albumin \>3.0 g/L. ii. Hemoglobin \>8.0 g/dL for women; \>9.0 g/dL for men. iii. Platelet count \>50,000/mm3. iv. Calculated creatinine clearance (CrCl) using Cockcroft-Gault method \>30 mL/min. v. Aspartate aminotransferase (AST/SGOT) \<10 times the upper limit of the normal range (ULN). vi. Alanine aminotransferase (ALT/SGPT) \<10 times the ULN. vii. Total bilirubin \<1.5 times the ULN for participants not on atazanavir (ATV) and \<3 times the ULN for participants on ATV. viii. International normalized ratio (INR) \<1.5 times the ULN. * Life expectancy greater than 1 year (as determined by study clinician) * Willing to initiate HCV treatment * Agree to be randomized to an adherence support strategy * Ability and willingness to provide written informed consent * Female participants of reproductive potential must not be pregnant * All female participants of reproductive potential must agree not to participate in a conception process * All female participants of reproductive potential must agree to use at least one reliable form of contraceptive while re…